Skip to main content

Advertisement

Log in

Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications

  • Review
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Pathological features of benign prostatic hyperplasia (BPH) dictate various responses to prostatic artery embolization (PAE). Typically, BPH originates in the transition zone and periurethral region, where should be considered the primary target area in PAE procedures. Given that histological heterogeneity of components in hyperplasia nodules, epithelial or stromal, identifying the more responsive nodules to PAE will have clinical implications. Since some lower urinary tract symptoms (LUTS) in patients with BPH are usually related to bladder outlet obstruction-induced changes in bladder function rather than to outflow obstruction directly, proper selection of candidate patients prior to PAE is of great clinical importance. BPH is a typical chronic progressive condition, suggesting PAE could aim not only to relieve LUTS but also to delay or prevent the clinical progression. Awareness of the pathological background of BPH is essential for interventional radiologists to improve clinical outcomes and develop new treatment strategies in clinical practice of PAE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.

    PubMed  CAS  Google Scholar 

  2. Pisco J, Campos Pinheiro L, Bilhim T, Duarte M, RioTinto H, Fernandes L, Vaz Santos V, Oliveira AG. Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results. Radiology. 2013;266(2):668–77.

    Article  PubMed  Google Scholar 

  3. Carnevale FC, da Motta-Leal-Filho JM, Antunes AA, Baroni RH, Marcelino AS, Cerri LM, Yoshinaga EM, Cerri GG, Srougi M. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol. 2013;24(4):535–42.

    Article  PubMed  Google Scholar 

  4. Bagla S, Martin CP, van Breda A, Sheridan MJ, Sterling KM, Papadouris D, Rholl KS, Smirniotopoulos JB, van Breda A. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2014;25(1):47–52.

    Article  PubMed  Google Scholar 

  5. Carnevale FC, Moreira AM, Antunes AA. The “PErFecTED technique”: proximal embolization first, then embolize distal for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2014;37(6):1602–5.

    Article  PubMed  Google Scholar 

  6. Golzarian J, Antunes AA, Bilhim T, Carnevale FC, Konety B, McVary KT, Parsons JK, Pisco JM, Siegel DN, Spies J, Wasserman N, Gowda N, Ahrar K. Prostatic artery embolization to treat lower urinary tract symptoms related to benign prostatic hyperplasia and bleeding in patients with prostate cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2014;25(5):665–74.

    Article  PubMed  Google Scholar 

  7. Roehrborn CG. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 10th ed. Philadelphia: Saunders; 2012. p. 2570–610.

    Chapter  Google Scholar 

  8. Madersbacher S, Klingler HC, Schatzl G, Stulnig T, Schmidbauer CP, Marberger M. Age related urodynamic changes in patients with benign prostatic hyperplasia. J Urol. 1996;156(5):1662–7.

    Article  PubMed  CAS  Google Scholar 

  9. Dmochowski RR. Bladder outlet obstruction: etiology and evaluation. Rev Urol. 2005;7(Suppl 6):S3–13.

    PubMed  PubMed Central  Google Scholar 

  10. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317(10):599–604.

    Article  PubMed  CAS  Google Scholar 

  11. Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology. 1984;114(6):2100–6.

    Article  PubMed  CAS  Google Scholar 

  12. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4 Pt 1):1399–403.

    Article  PubMed  CAS  Google Scholar 

  13. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 1991;145(2):405–9.

    PubMed  CAS  Google Scholar 

  14. Sonke GS, Mochtar CA, Kiemeney LALM. Etiology of benign prostatic hyperplasia. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. 2nd ed. Oxfordshire: Taylor & Francis; 2005. p. 2570–610.

    Google Scholar 

  15. Niu Y, Xu Y, Zhang J, Bai J, Yang H, Ma T. Proliferation and differentiation of prostatic stromal cells. BJU Int. 2001;87(4):386–93.

    Article  PubMed  CAS  Google Scholar 

  16. Kim IY, Zelner DJ, Sensibar JA, Ahn HJ, Park L, Kim JH, Lee C. Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res. 1996;222(1):103–10.

    Article  PubMed  CAS  Google Scholar 

  17. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology. 1998;139(11):4672–8.

    PubMed  CAS  Google Scholar 

  18. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1(3):157–62.

    Article  PubMed  Google Scholar 

  19. Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8(1):29–36.

    Article  PubMed  CAS  Google Scholar 

  20. Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999;53(3 Suppl 3a):1–6.

    Article  PubMed  CAS  Google Scholar 

  21. Ghafar MA, Puchner PJ, Anastasiadis AG, Cabelin MA, Buttyan R. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep. 2002;3(4):292–6.

    Article  PubMed  Google Scholar 

  22. Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer AE, Bartsch G, Frauscher F. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005;96(7):1073–8.

    Article  PubMed  Google Scholar 

  23. Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, Rantner B, Fraedrich G, Pallwein L, Aigner F, Horninger W, Frauscher F. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int. 2006;98(5):1038–42.

    Article  PubMed  Google Scholar 

  24. Deipolyi AR, Al-Ansari S, Khademhosseini A, Oklu R. Occlusion of the internal iliac artery is associated with smaller prostate and decreased urinary tract symptoms. J Vasc Interv Radiol. 2015;26(9):1305–10.

    Article  PubMed  Google Scholar 

  25. Claus S, Wrenger M, Senge T, Schulze H. Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol Res. 1993;21(5):305–8.

    Article  PubMed  CAS  Google Scholar 

  26. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968;49(3):347–57.

    PubMed  CAS  Google Scholar 

  27. Myers RP. Structure of the adult prostate from a clinician’s standpoint. Clin Anat. 2000;13(3):214–5.

    Article  PubMed  CAS  Google Scholar 

  28. McNeal JE. The zonal anatomy of the prostate. Prostate. 1981;2(1):35–49.

    Article  PubMed  CAS  Google Scholar 

  29. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978;15(4):340–5.

    PubMed  CAS  Google Scholar 

  30. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am. 1990;17(3):477–86.

    PubMed  CAS  Google Scholar 

  31. Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 1979;122(4):487–91.

    PubMed  CAS  Google Scholar 

  32. Aoki Y, Arai Y, Maeda H, Okubo K, Shinohara K. Racial differences in cellular composition of benign prostatic hyperplasia. Prostate. 2001;49(4):243–50.

    Article  PubMed  CAS  Google Scholar 

  33. Robert M, Costa P, Bressolle F, Mottet N, Navratil H. Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens. Br J Urol. 1995;75(3):317–24.

    Article  PubMed  CAS  Google Scholar 

  34. Lepor H, Shapiro E, Wang B, Liang YC. Comparison of the cellular composition of benign prostatic hyperplasia in Chinese and Caucasian-American men. Urology. 1996;47(1):38–42.

    Article  PubMed  CAS  Google Scholar 

  35. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol. 1992;147(5):1293–7.

    PubMed  CAS  Google Scholar 

  36. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992;21(4):297–307.

    Article  PubMed  CAS  Google Scholar 

  37. Bostwick DG. The pathology of benign prostatic hyperplasia. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. 2nd ed. Oxfordshire: Taylor & Francis; 2005. p. 97–111.

    Google Scholar 

  38. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol. 1989;141(2):243–7.

    PubMed  CAS  Google Scholar 

  39. Lynch TH, Waymont B, Dunn JA, Hughes MA, Wallace DM. Rapid diagnostic service for patients with haematuria. Br J Urol. 1994;73(2):147–51.

    Article  PubMed  CAS  Google Scholar 

  40. Hasan ST, German K, Derry CD. Same day diagnostic service for new cases of haematuria–a district general hospital experience. Br J Urol. 1994;73(2):152–4.

    Article  PubMed  CAS  Google Scholar 

  41. Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, Holmes SA. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000;163(2):496–8.

    Article  PubMed  CAS  Google Scholar 

  42. Foley SJ, Bailey DM. Microvessel density in prostatic hyperplasia. BJU Int. 2000;85(1):70–3.

    Article  PubMed  CAS  Google Scholar 

  43. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993;24(2):220–6.

    Article  PubMed  CAS  Google Scholar 

  44. Deering RE, Bigler SA, Brown M, Brawer MK. Microvascularity in benign prostatic hyperplasia. Prostate. 1995;26(3):111–5.

    Article  PubMed  CAS  Google Scholar 

  45. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol. 1996;155(2):595–600.

    Article  PubMed  CAS  Google Scholar 

  46. Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol. 2000;163(1):107–13.

    Article  PubMed  CAS  Google Scholar 

  47. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161(4):1174–9.

    Article  PubMed  CAS  Google Scholar 

  48. EzzelDin K, Kiemeney LA, de Wildt MJ, Debruyne FM, de la Rosette JJ. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology. 1996;48(3):393–7.

    Article  CAS  Google Scholar 

  49. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 1993;150(2 Pt 1):351–8.

    PubMed  CAS  Google Scholar 

  50. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481–7.

    Article  PubMed  CAS  Google Scholar 

  51. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol. 1999;162(4):1301–6.

    Article  PubMed  CAS  Google Scholar 

  52. McVary KT. Prostatic arterial embolization for LUTS/BPH-an opportunity for collaborative research or next prostatic gizmo candidate? J Urol. 2014;191(3):577–8.

    Article  PubMed  Google Scholar 

  53. Lepor H. Editorial comment to: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Stoner E and the Members of the Finasteride Study Group. Urology. 1994; 43(3): 292–293.

  54. Charlton RG, Morley AR, Chambers P, Gillespie JI. Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU Int. 1999;84(9):953–60.

    Article  PubMed  CAS  Google Scholar 

  55. O’Reilly BA, Kosaka AH, Chang TK, Ford AP, Popert R, McMahon SB. A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int. 2001;87(7):617–22.

    Article  PubMed  Google Scholar 

  56. Levin RM, Haugaard N, O’Connor L, Buttyan R, Das A, Dixon JS, Gosling JA. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000;19(5):609–29.

    Article  PubMed  CAS  Google Scholar 

  57. Jaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep. 2005;6(6):410–8.

    Article  PubMed  Google Scholar 

  58. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol. 1979;121(5):640–2.

    PubMed  CAS  Google Scholar 

  59. Rollema HJ, Van Mastrigt R. Improved indication and followup in transurethral resection of the prostate using the computer program CLIM: a prospective study. J Urol. 1992;148(1):111–5.

    PubMed  CAS  Google Scholar 

  60. Lemack GD, McConnell JD. Bladder responses to obstruction. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. 2nd ed. Oxfordshire: Taylor & Francis; 2005. p. 113–8.

    Google Scholar 

  61. George NJ, Feneley RC, Roberts JB. Identification of the poor risk patient with “prostatism” and detrusor failure. Br J Urol. 1986;58(3):290–5.

    Article  PubMed  CAS  Google Scholar 

  62. Kaplan SA, Bowers DL, Te AE, Olsson CA. Differential diagnosis of prostatism: A 12-year retrospective analysis of symptoms, urodynamics and satisfaction with therapy. J Urol. 1996;155(4):1305–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was not supported by any grants.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fei Sun.

Ethics declarations

Conflict of Interest

Authors declare that they have no Conflict of interest.

Human and Animal Informed Consent

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sun, F., Crisóstomo, V., Báez-Díaz, C. et al. Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications. Cardiovasc Intervent Radiol 39, 1–7 (2016). https://doi.org/10.1007/s00270-015-1233-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-015-1233-x

Keywords

Navigation